Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone765-463-4527
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.35 million
Profitability
Miscellaneous
Employees224
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions
What is Bioanalytical Systems' stock symbol?
Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."
How were Bioanalytical Systems' earnings last quarter?
Bioanalytical Systems, Inc. (NASDAQ:BASI) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.06) EPS for the quarter. The business earned $9.34 million during the quarter. Bioanalytical Systems had a negative net margin of 2.82% and a negative return on equity of 3.12%. View Bioanalytical Systems' Earnings History.
When is Bioanalytical Systems' next earnings date?
Has Bioanalytical Systems been receiving favorable news coverage?
Media headlines about BASI stock have been trending positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bioanalytical Systems earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Bioanalytical Systems' key competitors?
Some companies that are related to Bioanalytical Systems include Senomyx (SNMX), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Vitality Biopharma (VBIO), Tenax Therapeutics (TENX), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY), National Research (NRCIA), National Research (NRCIB), Redpoint Bio (RPBC) and VIRALYTICS Ltd/S (VRACY).
What other stocks do shareholders of Bioanalytical Systems own?
Who are Bioanalytical Systems' key executives?
Bioanalytical Systems' management team includes the folowing people:
- Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 49)
- Ms. Jill C. Blumhoff, CFO, VP of Fin. & Sec. (Age 43)
- Mr. Robert Leasure Jr., Pres, CEO & Director (Age 59)
- Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 74)
- Mr. D. Thomas Oakley, Chief Operating Officer
Who are Bioanalytical Systems' major shareholders?
Bioanalytical Systems' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.28%). Company insiders that own Bioanalytical Systems stock include Daniel Thomas Oakley, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff and Robert Jr Leasure. View Institutional Ownership Trends for Bioanalytical Systems.
Which institutional investors are buying Bioanalytical Systems stock?
BASI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Bioanalytical Systems stock in the last two years include Daniel Thomas Oakley, John E Sagartz, Peter Kissinger, Philip A Downing, R Matthew Neff and Robert Jr Leasure. View Insider Buying and Selling for Bioanalytical Systems.
How do I buy shares of Bioanalytical Systems?
Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioanalytical Systems' stock price today?
One share of BASI stock can currently be purchased for approximately $1.9250.
How big of a company is Bioanalytical Systems?
Bioanalytical Systems has a market capitalization of $19.81 million and generates $26.35 million in revenue each year. Bioanalytical Systems employs 224 workers across the globe.
What is Bioanalytical Systems' official website?
How can I contact Bioanalytical Systems?
Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected]
MarketBeat Community Rating for Bioanalytical Systems (NASDAQ BASI)
MarketBeat's community ratings are surveys of what our community members think about Bioanalytical Systems and other stocks. Vote "Outperform" if you believe BASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
